Respirology Search

Respirology

Respirology

Home News Diseases Conferences Special Reports Multimedia

IDIOPATHIC PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Idiopathic%20pulmonary%20fibrosis News

News

Serum HMGB1 predicts onset, severity of AE-IPF

20200320110000

Increased levels of serum high-mobility group box 1 (HMGB1) is associated with earlier onset of acute exacerbation (AE) in stable idiopathic pulmonary fibrosis (IPF) patients and shorter survival in those with AE-IPF, a recent study has shown. This signifies that HMGB1 predicts the acute deterioration of IPF.

Chronic viral infection a risk factor for idiopathic pulmonary fibrosis

20191219090000

Persistent or chronic viral infections, such as Epstein-Barr virus and cytomegalovirus, may promote the development, but not exacerbation, of idiopathic pulmonary fibrosis, according to the results of a meta-analysis.

Molecular breath analysis helps speed up screening for IPF

20190524110000

Real-time exhaled breath analysis using secondary electrospray ionization-mass spectrometry has validated previous findings of elevated lung tissue amino acid levels in idiopathic pulmonary fibrosis (IPF), claims a new study, suggesting that online breath analysis can be a practical tool for rapid screening for IPF.

Age, family aggregation, haematological abnormalities predict telomere shortening in IPF patients

20190125120000

Patients with sporadic idiopathic pulmonary fibrosis (IPF) aged <60 years and who have nonspecific immunological or haematological abnormalities are at increased risk of telomere shortening, as well as present a poorer prognosis, according to a study.

Pirfenidone may protect against progression, death in idiopathic pulmonary fibrosis

20181212140000

Treatment with pirfenidone may lead to significantly reduced risks of multiple progression events and death in patients with idiopathic pulmonary fibrosis, according to a study.

INPULSIS-ON validates long-term safety of nintedanib for IPF

Roshini Claire Anthony, 20181004140209

INPULSIS-ON*, the open-label extension of the phase III INPULSIS trials, demonstrated the safety of nintedanib over a long-term period of treatment in patients with idiopathic pulmonary fibrosis (IPF).

Glucocorticoids may confer adverse outcomes in patients with suspected IPF

20180402090000

There have been a substantial number of severe adverse events (SAE) and a faster decrease in forced vital capacity (FVC) in patients with possible idiopathic pulmonary fibrosis (posIPF) taking steroid therapy, a new study has shown.

Pulmonary hypertension risk in CPFE linked to summed extents of ILD, emphysema

20171231100000

Patients with combined pulmonary fibrosis and emphysema (CPFE) are likely to develop pulmonary hypertension, and this likelihood may be explained by the summed extents of interstitial lung disease (ILD) and emphysema, according to a study.

Glucocorticoids linked to unfavourable outcomes in patients with suspected IPF

20171222140000

Treatment with glucocorticoid appears to be associated with an accelerated decline in forced vital capacity and a substantial number of serious adverse events among patients with possible idiopathic pulmonary fibrosis (IPF), according to a study.

GORD diagnosis, treatment has little bearing on IPF survival

Roshini Claire Anthony, 20171205140300

Being diagnosed or treated for gastro-oesophageal reflux disease (GORD) has little impact on the survival outcomes of patients with idiopathic pulmonary fibrosis (IPF), according to a study presented as a poster at APSR 2017.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!

Lower joint replacement risk yet another benefit of statins

Yesterday

Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.

Migraine a risk factor for dementia?

Pearl Toh, 29 Jun 2020

Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.

Daily alcohol intake, certain drugs tied to liver abnormalities in PsA patients

30 Jun 2020

Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.

Pembrolizumab + chemo improves PFS in previously untreated, advanced TNBC

Christina Lau, 5 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.